UK markets closed
  • NIKKEI 225

    29,642.69
    +21.70 (+0.07%)
     
  • HANG SENG

    28,793.14
    -107.69 (-0.37%)
     
  • CRUDE OIL

    63.33
    +0.18 (+0.29%)
     
  • GOLD FUTURES

    1,767.20
    +30.90 (+1.78%)
     
  • DOW

    33,995.99
    +265.10 (+0.79%)
     
  • BTC-GBP

    45,537.83
    -744.77 (-1.61%)
     
  • CMC Crypto 200

    1,375.22
    -5.72 (-0.41%)
     
  • ^IXIC

    14,024.12
    +166.28 (+1.20%)
     
  • ^FTAS

    3,988.72
    +24.05 (+0.61%)
     

Worldwide Acute Lymphoblastic Leukemia Treatment Industry to 2025 - Growing Healthcare Expenditure Presents Opportunities

Research and Markets
·8-min read

Dublin, March 23, 2021 (GLOBE NEWSWIRE) -- The "Acute Lymphoblastic Leukemia Treatment Market Research Report by Types of Cell - Global Forecast to 2025 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering.

The Global Acute Lymphoblastic Leukemia Treatment Market is expected to grow from USD 2,694.18 Million in 2020 to USD 3,509.05 Million by the end of 2025.

Market Segmentation & Coverage:

This research report categorizes the Acute Lymphoblastic Leukemia Treatment to forecast the revenues and analyze the trends in each of the following sub-markets:

  • Based on Types of Cell, the Acute Lymphoblastic Leukemia Treatment Market is examined across B-cell ALL, Philadelphia chromosome: Positive (Ph+) and negative (Ph-), and T-cell ALL.

  • Based on Therapy, the Acute Lymphoblastic Leukemia Treatment Market is examined across Chemotherapy, Radiation Therapy, Stem Cell Transplantation, and Targeted Therapy. The Chemotherapy further studied across CALGB 8811 Regimen, Hyper - CVAD Regimen, Linker Regimen, and Nucleoside Inhibitors.

  • Based on Geography, the Acute Lymphoblastic Leukemia Treatment Market is examined across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Company Usability Profiles:

The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Acute Lymphoblastic Leukemia Treatment Market including Amgen Inc, Baxter International, Inc., Bio-Techne Corporation, Bristol Myer Squibb Company, Calyxt Inc., Eisai Co Ltd, Erytech Pharma S.A., F. Hoffmann-La Roche AG, Genmab A/S, Genmab AS, Gilead Sciences, Inc., GlaxoSmithKline PLC, HORIBA, Ltd., Jazz Pharmaceuticals PLC, Novartis International AG, Pfizer Inc, Sanofi S.A, Spectrum Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, and Vimeo, LLC.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. the ongoing research amplifies the research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Acute Lymphoblastic Leukemia Treatment Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments

The report answers questions such as:
1. What is the market size and forecast of the Global Acute Lymphoblastic Leukemia Treatment Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Acute Lymphoblastic Leukemia Treatment Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Acute Lymphoblastic Leukemia Treatment Market?
4. What is the competitive strategic window for opportunities in the Global Acute Lymphoblastic Leukemia Treatment Market?
5. What are the technology trends and regulatory frameworks in the Global Acute Lymphoblastic Leukemia Treatment Market?
6. What are the modes and strategic moves considered suitable for entering the Global Acute Lymphoblastic Leukemia Treatment Market?

Key Topics Covered:

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Stakeholders

2. Research Methodology
2.1. Research Process
2.1.1. Define: Research Objective
2.1.2. Determine: Research Design
2.1.3. Prepare: Research Instrument
2.1.4. Collect: Data Source
2.1.5. Analyze: Data Interpretation
2.1.6. Formulate: Data Verification
2.1.7. Publish: Research Report
2.1.8. Repeat: Report Update
2.2. Research Execution
2.2.1. Initiation: Research Process
2.2.2. Planning: Develop Research Plan
2.2.3. Execution: Conduct Research
2.2.4. Verification: Finding & Analysis
2.2.5. Publication: Research Report
2.3. Research Outcome

3. Executive Summary
3.1. Introduction
3.2. Market Outlook
3.3. Types of Cell Outlook
3.4. Therapy Outlook
3.5. Geography Outlook
3.6. Competitor Outlook

4. Market Overview
4.1. Introduction
4.2. Cumulative Impact of COVID-19

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of acute lymphoblastic leukemia
5.1.1.2. Increasing cancer awareness programs and strong product pipeline
5.1.1.3. Rising R&D activities for the innovation of novel therapies
5.1.1.4. Advancement in molecular biology and pharmacology for development of novel drugs
5.1.2. Restraints
5.1.2.1. High cost of treatment
5.1.3. Opportunities
5.1.3.1. Rising awareness programs for acute lymphoblastic leukemia treatment
5.1.3.2. Growing in healthcare expenditure
5.1.3.3. Increase investment in the R&D of different leukemia
5.1.4. Challenges
5.1.4.1. Stringent regulatory policies
5.1.4.2. Adverse effects associated with the treatment, and complications with chemotherapy
5.2. Porters Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Threat of Substitutes
5.2.3. Bargaining Power of Customers
5.2.4. Bargaining Power of Suppliers
5.2.5. Industry Rivalry

6. Global Acute Lymphoblastic Leukemia Treatment Market, By Types of Cell
6.1. Introduction
6.2. B-cell ALL
6.3. Philadelphia chromosome: Positive (Ph+) and negative (Ph-)
6.4. T-cell ALL

7. Global Acute Lymphoblastic Leukemia Treatment Market, By Therapy
7.1. Introduction
7.2. Chemotherapy
7.2.1. CALGB 8811 Regimen
7.2.2. Hyper - CVAD Regimen
7.2.3. Linker Regimen
7.2.4. Nucleoside Inhibitors
7.3. Radiation Therapy
7.4. Stem Cell Transplantation
7.5. Targeted Therapy

8. Americas Acute Lymphoblastic Leukemia Treatment Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States

9. Asia-Pacific Acute Lymphoblastic Leukemia Treatment Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. South Korea
9.10. Thailand

10. Europe, Middle East & Africa Acute Lymphoblastic Leukemia Treatment Market
10.1. Introduction
10.2. France
10.3. Germany
10.4. Italy
10.5. Netherlands
10.6. Qatar
10.7. Russia
10.8. Saudi Arabia
10.9. South Africa
10.10. Spain
10.11. United Arab Emirates
10.12. United Kingdom

11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis
11.3. Market Share Analysis
11.4. Competitor SWOT Analysis
11.5. Competitive Scenario
11.5.1. Merger & Acquisition
11.5.2. Agreement, Collaboration, & Partnership
11.5.3. New Product Launch & Enhancement
11.5.4. Investment & Funding
11.5.5. Award, Recognition, & Expansion

12. Company Usability Profiles
12.1. Amgen Inc
12.2. Baxter International, Inc.
12.3. Bio-Techne Corporation
12.4. Bristol Myer Squibb Company
12.5. Calyxt Inc.
12.6. Eisai Co Ltd
12.7. Erytech Pharma S.A.
12.8. F. Hoffmann-La Roche AG
12.9. Genmab A/S
12.10. Genmab AS
12.11. Gilead Sciences, Inc.
12.12. GlaxoSmithKline PLC
12.13. HORIBA, Ltd.
12.14. Jazz Pharmaceuticals PLC
12.15. Novartis International AG
12.16. Pfizer Inc
12.17. Sanofi S.A
12.18. Spectrum Pharmaceuticals, Inc.
12.19. Takeda Pharmaceutical Company Limited
12.20. Vimeo, LLC

13. Appendix

For more information about this report visit https://www.researchandmarkets.com/r/211tbe

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900